Human innate lymphoid cells have been described to exist in different organs, with functional deregulation of these cells contributing to several disease states. Here, we performed the first detailed characterization of the phenotype, tissue-residency properties, and functionality of ILC1s, ILC2s, and ILC3s in the human adult and fetal liver. In addition, we investigated changes in the ILC compartment in liver fibrosis. A unique composition of tissue-resident ILCs was observed in nonfibrotic livers as compared with that in mucosal tissues, with NKp44 − ILC3s accounting for the majority of total intrahepatic ILCs. The frequency of ILC2s, representing a small fraction of ILCs in nonfibrotic livers, increased in liver fibrosis and correlated directly with the severity of the disease. Notably, intrahepatic ILC2s secreted the profibrotic cytokine IL-13 when exposed to IL-33 and thymic stromal lymphopoetin (TSLP); these cytokines were produced by hepatocytes, hepatic stellate cells (HSCs), and Kupffer cells in response to TLR-3 stimulation. In summary, the present results provide the first detailed characterization of intrahepatic ILCs in human [8, [10] [11] [12] [13] . Recently, ILCs have been characterized in various human organs and are increasingly being recognized to play important roles during homeostasis and disease [5, 6, [10] [11] [12] [13] [14] [15] [16] . Liver fibrosis is the consequence of sustained liver damage accompanied by a progressive accumulation of extracellular matrix (ECM) proteins. The major causes underlying liver fibrosis are chronic hepatitis C virus infection, alcohol abuse, and nonalcoholic steatohepatitis [17] . The end stage of hepatic fibrosis, liver cirrhosis, is accompanied by an increased risk for portal hypertension, liver failure, and liver cancer [18] . Activated hepatic stellate cells (HSCs) have been suggested as the main producers of ECM proteins, thus playing a key role in liver fibrosis [19, 20] . To date, several profibrotic cytokines have been identified. One of the most potent is TGF-β1, which acts as an inducer of collagen production in HSCs [21] . Moreover, IL-13 is known to promote tissue fibrosis [22] and increased IL-13 levels were found in fibrotic liver tissue of patients infected with S. japonicum [23] . Interestingly, in mouse models of S. mansoni infection ILC2s mediated lung fibrosis [24] and IL-13 was identified as a driver of hepatic fibrosis [25] . Moreover, a mechanism involving ILC2s in fibrosis development in the mouse liver was recently suggested [26] . Although animal models of liver fibrosis have previously provided important insights into disease mechanisms, the human and mouse liver differ substantially, particular with respect to immune cell composition [27] . Since the role for ILCs in the development of human liver fibrosis remains obscure, studies on patient material provide valuable insights into disease pathogenesis in humans.
Human innate lymphoid cells have been described to exist in different organs, with functional deregulation of these cells contributing to several disease states. Here, we performed the first detailed characterization of the phenotype, tissue-residency properties, and functionality of ILC1s, ILC2s, and ILC3s in the human adult and fetal liver. In addition, we investigated changes in the ILC compartment in liver fibrosis. A unique composition of tissue-resident ILCs was observed in nonfibrotic livers as compared with that in mucosal tissues, with NKp44 − ILC3s accounting for the majority of total intrahepatic ILCs. The frequency of ILC2s, representing a small fraction of ILCs in nonfibrotic livers, increased in liver fibrosis and correlated directly with the severity of the disease. Notably, intrahepatic ILC2s secreted the profibrotic cytokine IL-13 when exposed to IL-33 and thymic stromal lymphopoetin (TSLP); these cytokines were produced by hepatocytes, hepatic stellate cells (HSCs), and Kupffer cells in response to TLR-3 stimulation. In summary, the present results provide the first detailed characterization of intrahepatic ILCs in human
Introduction
Innate lymphoid cells (ILCs) are a heterogeneous group of innate immune cells with a lymphoid morphology, comprising NK cells and the more recently described subsets of non-NK ILCs. These noncytotoxic ILCs commonly express the IL-7 receptor α-chain (CD127) and depend on IL-7 signaling for their development [1] . CD127 + ILCs are divided into three subpopulations based on their cytokine secretion-profile and the expression of transcription factors, mirroring the classification of T helper cells [1] . Group 3 ILCs (ILC3s) are dependent on RORγt for their development and produce the signature cytokines IL-22 and/or IL-17, where IL-22 is produced mainly by the ILC3 subset expressing the natural cytotoxicity receptor NKp44 [2] [3] [4] . ILC3s also include lymphoid tissue inducer cells (LTi), which are important in formation of lymph nodes during fetal development [3] . Group 1 ILCs (ILC1s) are defined by the expression of Tbet and production of IFN-γ [5] . This group also includes cytotoxic ILC1s such as conventional natural killer cells (cNK) and a subset of CD103 + intraepithelial ILC1s in the gut [6] . Group 2 ILCs (ILC2s) depend on the transcription factors GATA3 [7, 8] and RORα [9] for their development and function. ILC2s secrete the type 2 cytokines IL-13 and IL-5 upon stimulation with IL-25, IL-33, or thymic stromal lymphopoetin (TSLP) [8, [10] [11] [12] [13] . Recently, ILCs have been characterized in various human organs and are increasingly being recognized to play important roles during homeostasis and disease [5, 6, [10] [11] [12] [13] [14] [15] [16] . Liver fibrosis is the consequence of sustained liver damage accompanied by a progressive accumulation of extracellular matrix (ECM) proteins. The major causes underlying liver fibrosis are chronic hepatitis C virus infection, alcohol abuse, and nonalcoholic steatohepatitis [17] . The end stage of hepatic fibrosis, liver cirrhosis, is accompanied by an increased risk for portal hypertension, liver failure, and liver cancer [18] . Activated hepatic stellate cells (HSCs) have been suggested as the main producers of ECM proteins, thus playing a key role in liver fibrosis [19, 20] . To date, several profibrotic cytokines have been identified. One of the most potent is TGF-β1, which acts as an inducer of collagen production in HSCs [21] . Moreover, IL-13 is known to promote tissue fibrosis [22] and increased IL-13 levels were found in fibrotic liver tissue of patients infected with S. japonicum [23] . Interestingly, in mouse models of S. mansoni infection ILC2s mediated lung fibrosis [24] and IL-13 was identified as a driver of hepatic fibrosis [25] . Moreover, a mechanism involving ILC2s in fibrosis development in the mouse liver was recently suggested [26] . Although animal models of liver fibrosis have previously provided important insights into disease mechanisms, the human and mouse liver differ substantially, particular with respect to immune cell composition [27] . Since the role for ILCs in the development of human liver fibrosis remains obscure, studies on patient material provide valuable insights into disease pathogenesis in humans.
Here, we investigated the distribution, phenotype, and function of ILC subsets in the human adult and fetal liver. Additionally, we addressed the presence of ILC subsets in human fibrotic liver tissue. Our results demonstrate that the composition of ILCs in the liver is unique as compared with gut and tonsil and that intrahepatic ILCs are most likely tissue-resident cells. Furthermore, the phenotype of adult and fetal liver differs markedly, as only fetal liver ILC3s express the LTi marker NRP1. In addition, we demonstrate that the frequency of intrahepatic ILC2s correlates with the degree of liver fibrosis, and IL-33 and TSLP, produced by TLR3-stimulated hepatocytes, HSCs and Kupffer cells promote production of potentially profibrotic IL-13 from ILC2s. These first data on human intrahepatic ILC characteristics in health and fibrosis might have clinical implications, as targeting ILCs may represent a therapeutic strategy for the treatment of liver fibrosis.
Results

All groups of innate lymphoid cells are present in the human liver
We set out to investigate the composition of ILCs with special emphasis on non-NK ILCs in fresh liver cell suspensions. Cells were isolated from tumor-free areas of nonfibrotic human livers. Within the fraction of CD45 + cells lacking lineage markers (Lin − ), the majority of cells expressed CD56 (Fig. 1A) . Most of these cells lacked expression of CD127.
were readily identified as intrahepatic NK cells. The majority of these cells were CD56 bright (Fig. 1A) , expressed NKG2A but lacked CD16 (data not shown), which is in sharp contrast to the peripheral blood compartment where cytotoxic CD56 dim NKG2A − CD16
+ cells are more prevalent [28, 29] . In addition, we also identified CD45 + Lin − cells expressing CD127 and lacking the NK cell markers NKG2A and CD16, indicating that these cells belong to the non-NK ILC lineages (Fig. 1A) . Similar to ILCs that were previously described in skin, gut, and upper airways [5, 13, 15] , the CD45 + Lin − CD127 + CD16 − NKG2A − ILCs could be subgrouped into four distinct populations on the basis of CRTH2, CD117, and NKp44 expression, identifying ILC2s [13] , ILC1s [5] , NKp44 + , and NKp44 − ILC3s [2, 4, 5] . All ILCs expressed the pan-ILC marker CD161 (Fig. 1A) . By analyzing transcription factors specifically associated with the development and function of NK cells (Eomes and Tbet), ILC1s (Tbet), ILC2s (GATA3), and ILC3s (RORγ(t), Helios, and AHR), we could confirm the identity of the ILC subpopulations (Fig. 1B) . NK cells expressed Tbet and Eomes. The majority of intrahepatic ILC1s expressed Tbet and intermediate levels of RORγ(t) (Fig. 1B) 1B) and Helios (Fig. 1C) , which was previously shown to be expressed by ILC3s in human tonsils [6, 13] . Interestingly, in contrast to ILC3s in tonsils (Supporting Information Fig. 1A ), intrahepatic ILC3s lacked detectable expression of AHR (Fig. 1C) . Despite this, when analyzing intrahepatic ILC3s expanded in vitro, ILC3s produced IL-22 at frequencies comparable to tonsil ILC3s (Supporting Information Fig. 1B ). In summary, these data demonstrate that all currently described noncytotoxic ILC populations can be found in the human liver and that intrahepatic ILCs share a similar transcription factor profile with ILC subsets found in mucosal tissues such as gut and tonsil.
The intrahepatic ILC compartment is uniquely composed and differs between adult and fetal livers
We next set out to evaluate the overall composition of the ILC family in the human liver compared to gut and tonsil, mucosal sites where ILCs have previously been characterized [5, 30] . CD56 + NK cells dominated in the liver compared to the other organs ( Fig. 2A) . Lin − CD127 + ILCs were present at comparable frequencies in the liver and tonsil, with the highest frequency found in gut (Fig. 2B) . Overall, the liver had a distinct ILC subset composition compared to gut and tonsil. ILC1s and ILC2s were more frequent in the liver, especially compared to the gut where these cells were barely detectable (Fig. 2C ). In contrast, NKp44 + ILC3s were relatively rare in the liver as compared to gut and tonsil. Instead, NKp44 − ILC3s was the most frequent ILC population in the liver (Fig. 2D ).
To analyze intrahepatic ILCs in more detail we performed an extensive characterization of the phenotype of the ILC populations including markers of tissue residency. All ILC subsets exhibited hallmarks of tissue-resident cells with high expression of CD69 and absence of CD62L (Fig. 2E) . Interestingly, CD49a and CD103, previously shown to be expressed by distinct subsets of intrahepatic NK cells [29] and intraepithelial ILC1s and ILC3s [6, 31] were only expressed by a minor proportion of each ILC subset (Fig. 2E) . On average 5% of the intrahepatic NK cells expressed CD49a. Furthermore, CD103, which is expressed by epithelium-associated ILC3s [31] and intraepithelial ILC1s [6] was absent on all intrahepatic ILC subsets. These data indicate that intrahepatic ILCs, although likely tissueresident, do not utilize CD49a or CD103 for retention in the tissue.
Furthermore, the majority of intrahepatic non-NK ILCs lacked expression of the NK-cell receptors NKG2D expressed only low levels of NKp46 (Supporting Information Fig. 2 ). CD11a, which has been suggested to discriminate between NK cells and ILC3s [32] was expressed at high levels by NK cells, ILC1s, and ILC2s, whereas it was expressed at an intermediate level on intrahepatic ILC3s (Supporting Information Fig. 2 ). The chemokine receptor CXCR3 was expressed by a fraction of intrahepatic ILC1s (Supporting Information Fig. 2 ), in accordance with a previous report of CXCR3-expression on ILC1s found in Crohn's disease ileum [5] . A small fraction of ILC3s in the human tonsil and gut expresses the MHC class II molecule HLA-DR and mouse ILC3s expressing MHC-II regulate homeostais of gut T cells [30, 33] . In the liver, a substantial proportion of all intrahepatic ILC subsets expressed HLA-DR (Fig. 2F ) suggesting that they could be involved in the regulation of intrahepatic T cells. Finally, we examined the expression of the cell surface receptor neuropilin-1 (NRP1), a marker of lymphoid tissue inducer (LTi) cell activity in mice and humans [34] . NRP1 was absent from all adult intrahepatic ILC subsets ( Fig. 2F ), indicating that not even NKp44 − ILC3s, which are phenotypically similar to LTi cells, possess LTi activity.
Next, we investigated whether the composition and phenotype of intrahepatic ILCs in adult livers was similar to that in fetal livers, or if substantial changes occur after birth. Fetal livers collected at gestational week (gw) 6-20 contained almost exclusively NKp44 − ILC3s ( Fig. 3A and B) . The other ILC subsets, ILC1s, ILC2s, and NKp44 + ILC3s, were absent through gw 6-10 and only started to be detectable from gw 15 onwards (data not shown). In contrast to adult livers, a smaller proportion of fetal ILCs expressed CD69 (Fig. 3C ). Moreover, HLA-DR was expressed at lower levels as compared to the adult intrahepatic ILCs. As expected, considering the pronounced lymphoid organogenesis occurring during fetal development, the majority of fetal ILC3s expressed NRP1, likely representing LTi cells (Fig. 3D ). Similar to the adult liver, CD49a expression could only be detected on a small fraction of ILCs.
Taken together, these data show that all ILC populations are present in the human liver with a composition significantly different from the one found in gut and tonsil. Furthermore, the differences observed in the adult and fetal ILC compartment highlight potential discrepancies in ILC function dependent on age.
The frequency of intrahepatic ILC2s correlates with the severity of liver fibrosis
Several cytokines produced by subsets of ILCs, including IL-13 and IL-22 have been associated with the development of liver fibrosis [22, 35] . Therefore, we assessed the composition of ILC subsets in fibrotic livers. Although no difference in the total frequency of NK cells or Lin − CD127 + ILCs could be seen between livers with no or mild fibrosis (grade 0-2) and severely fibrotic or cirrhotic livers (grade 3-4) (Fig. 4A ), important differences were detected within the Lin − CD127 + ILC compartment. The frequency of ILC2s was more than doubled, whereas the frequency of NKp44 − ILC3s was reduced in severe fibrosis (Fig. 4B ). Noteworthy, the frequency of ILC2s directly correlated with the severity of liver fibrosis (Fig. 4C ). The frequency of ILC2s was also increased in severe fibrosis when evaluating the percentage of ILC2s out of total CD45 + and total CD3 − cells ( Fig. 4D and E) . This was not seen for NKp44 − ILC3s, where the frequency expressed as a percentage of CD45 + and CD3 − cells was similar between mild and severe fibrosis (Supporting Information Fig. 3 ). Interestingly, no change in the frequency of CD3 + CRTH2 + cells, representing mainly Th2 cells [36] , was observed (Fig. 4F) . To further validate our findings from fresh liver samples, we repeated the analysis on a cohort of frozen mononuclear cells from human liver tissue. Also in this cohort, we detected a good correlation between ILC2 frequency and fibrosis score (Supporting Information Fig. 4) . The transcription factor expression of ILC2s from severely fibrotic livers, with expression of GATA3, intermediate levels of RORγ(t), but no Tbet (Fig. 4G ), was consistent with the profile of ILC2s from nonfibrotic livers (Fig. 1B) . Intrahepatic ILC2s from livers with fibrosis expressed high levels of CD69 and low levels of CD62L, as observed in nonfibrotic livers, but distinct from peripheral blood ILC2s (Fig. 4H) . These data excluded that the enrichment of ILC2s in severely fibrotic/cirrhotic livers was due to contamination by ILCs from peripheral blood.
IL-33 and TSLP are produced in the liver and triggered by TLR3 challenge
In other organs, including blood, tonsil, skin, and airways [8, 13, 15] , ILC2s are activated by cytokines, including IL-25, IL-33, and TSLP. In order to identify the potential trigger of ILC2 activity in fibrotic livers, we assessed the expression of IL25, IL33, and TSLP in whole liver lysates. Only IL33 expression could be detected (Fig. 5A ) and was confirmed on the protein level by immunohistochemistry showing that IL-33 was produced in both nonfibrotic and fibrotic livers (Fig. 5B) . A quantification of these stainings showed no significant difference in the expression levels of IL-33 in nonfibrotic compared to fibrotic liver tissue (data not shown). Additionally, no significant difference in IL-33 expression between fibrotic and nonfibrotic areas of fibrosis-affected livers was observed (data not shown). However, since in severe fibrosis much of the tissue is replaced by ECM proteins, we wanted to study the expression of IL33 in specific liver cell subsets under the influence of a fibrosis-relevant stimulus. IL-33 is produced and released upon cellular stress caused by, for example, activation by virally encoded TLR-ligands [8] . Hence, as a model stimuli we chose poly(I:C), a TLR3 agonist, that to some degree mimics the effects of a hepatitis C infection [37] , a known cause of liver fibrosis.
As IL-33 production by hepatocytes and HSCs has been shown [37, 38] , we assessed IL33 expression upon poly(I:C) stimulation in primary hepatocytes from nonfibrotic livers and the hepatic stellate cell line LX2 [39] . Indeed, poly(I:C)-stimulation led to an increase in IL33 expression in both cell types (Fig. 5C and  D) . Furthermore, IL-33 production has been reported in lung macrophages [40] . We therefore sorted CD14 + CD163 + Kupffer cells from nonfibrotic livers and exposed them to poly(I:C). Whereas IL33 was not detected in resting Kupffer cells, poly(I:C) stimulation lead to a highly variable (4-96-fold), yet consistent increase in IL33 expression (Fig. 5E ). Poly(I:C) also boosted TSLP expression in all analyzed cell types (Fig. 5C, D , and E), but its expression was possibly too low to be detected in the whole liver lysates (Fig. 5A ).
Intrahepatic ILC2s produce IL-13 in response to IL-33 and TSLP
We next investigated the effects of IL-33 and TSLP on intrahepatic ILC2s. To assess the function of this small cell population with limited availability of primary human tissues, we used expanded cell lines of primary intrahepatic ILC2s [13] . After 10-14 days of culture, intrahepatic ILC2s maintained their surface phenotype with expression of CRTH2, CD127 (albeit downregulated), CD161, and CD117. NK/ILC3-associated markers NKp44 and CD56 were absent or expressed by a minority of the expanded ILC2s, respectively (Fig. 6A) . Upon PMA/ionomycin stimulation, ILC2s showed the archetypical cytokine profile, producing IL-13 and TNFα (Fig. 6B) . Interestingly, most ILC2s also produced IL-2 and GM-CSF, the latter being implicated in Kupffer cell maturation and function [41] . Surprisingly, most expanded ILC2s produced IFN-γ and a small fraction of cells produced some IL-22. As observed in other organs [8, 13] , intrahepatic ILC2s responded to IL-33 or TSLP with substantial IL-13 production and the combination exerted a synergistic effect (Fig. 6C) . Although PMA/ionomycin potently triggered IFN-γ production, only low levels of IFN-γ were secreted upon the more physiological IL-33 and TSLP stimulation. Of note, intrahepatic ILC2s did not produce TGF-β1, neither at resting nor IL-33/TSLP activated conditions (data not shown). Additionally, we validated the cytokine profile of intrahepatic ILC2s by assessing production of IL-13, IL-5, and IL-4 from freshly isolated, noncultured, intrahepatic ILC2s (on average 3000 ILC2s/analysis) in response to PMA/ionomycin stimulation (Fig.  6D) . IL-13, IL-5, and IL-4 was detected from all analyses of ILC2s, whereas only one out of three ILC3 samples showed production of these cytokines at much lower levels.
Discussion
In this study, we investigated the distribution, phenotype, and function of the hitherto uncharacterized ILC compartment in the human adult and fetal liver. In the adult liver, we identified all described populations of human Lin − CD127 + ILCs, including ILC1s, ILC2s, NKp44 − ILC3s as well as NKp44 + ILC3s, speaking for a possible role of ILCs in liver homeostasis and disease. The phenotypes of these ILC populations largely corresponded to those of previously characterized ILC1-3s in human mucosal tissues such as the gut and tonsil [5, 13] . Within the Tbet + ILC1s a small fraction of cell expressed the transcription factor Eomes. This transcription factor profile would be in line with intraepithelial ILC1s or NK cells [6] . previously been shown to be expressed by ILC3s in mouse and humans [30, 44] and NRP1 was demonstrated to be a marker of cells with LTi activity [34] . Our data suggest that fetal, but not adult liver NKp44 − ILC3s are LTi cells contributing to lymphoid organogenesis. Recently, it was shown that mouse ILCs are tissue-resident cells [45] and a population of tissue-resident human NK cells marked by CD49a expression was identified in human liver [29] . Intrahepatic ILCs, although showing only low expression of CD49a on a small fraction of cells, expressed the activation, and tissueresidency marker CD69 and did not express CD62L, indicating a tissue-resident phenotype. CD69 interferes with tissue egress of lymphocytes [46] and CD62L is a marker of lymphoid tissue homing, which is generally absent on lymphocytes within tissues [47] . Interestingly, CD69 was only lowly expressed on a minority of fetal intrahepatic ILCs, indicating that fetal ILCs might not be tissueresident. It is therefore possible that the human fetal liver is a source of LTi cells seeding other organs during development.
Our study of disease-affected fibrotic livers points toward a role for ILC2s in human liver fibrosis. We identified a direct correlation between the frequency of intrahepatic ILC2s and the degree of liver fibrosis. Importantly, the frequency of the adaptive counterpart of ILC2s, CRTH2 + T cells, was not altered in liver fibrosis, suggesting that type 2 skewing of the lymphocyte compartment in liver fibrosis might be an innate, rather than an adaptive phenomenon.
Recently, it was shown that severe-combined immunodeficiency patients are lacking ILCs before and after nonmyeloablative hematopoietic stem cell transplantation [48] . This lack of ILCs had no obvious impact on the susceptibility to infections or inflammation. Even though these data are pointing toward a redundant function of ILCs under normal conditions it might be that ILCs play a crucial role in specific pathogenic settings, for instance infection with helminths or certain bacteria that are encountered rarely in countries with a high hygienic standard. Furthermore, studies that systematically investigate the very long-term effects of absence of ILCs or the kinetics of infections in these patients would be needed to clarify the role of ILCs for health and disease. Our observation that only the ILC2 but not the Th2 frequency is altered in liver fibrosis points toward a unique function of ILC2s in this disease setting.
In this study, IL33 mRNA and IL-33 protein, a known activator of ILC2s, were found to be expressed in both healthy and cirrhotic livers. In humans, IL-33 expression has previously been shown in hepatocytes [37] and HSCs [38] . Hence, we set out to determine the potential trigger for IL-33 secretion in these particular hepatic cell types. We could identify primary hepatocytes, HSCs, and Kupffer cells as cellular sources of IL-33 and TSLP following TLR3-activation, as a model for hepatitis C infection. Production of these cytokines could potentially cause the accumulation of ILC2s in fibrotic livers. Although we could not detect TSLP in liver tissue lysates, the induction of TSLP after poly(I:C) stimulation in the different liver cell types could indicate a role for TSLP in human liver fibrosis via ILC2 activation. Indeed, there are reports suggesting a profibrotic effect of TSLP [49] [50] [51] . In addition to cytokine-induced proliferation of ILC2s in liver fibrosis, we are also raising the possibility that the accumulation of ILC2s might be the result of plasticity among ILCs. The observed simultaneous reduction of NKp44-ILC3s in fibrotic livers could indicate a plastic change into ILC2s. This hypothesis is also supported by the overall frequency of ILCs that remains unchanged in healthy and fibrotic livers.
IL-33 and TSLP are known to induce IL-13 secretion from ILC2s in other tissues [8, 13, 15] . We confirmed this effect in intrahepatic ILC2s, where stimulation with both cytokines synergistically induced high levels of IL-13. This finding is relevant since IL-13 has been suggested to be a profibrotic cytokine in liver fibrosis [23, 25, 26] . In one of these previous studies [26] , IL-33 overexpression in liver injury was accompanied by an accumulation of ILC2s and increased hepatic collagen, which was attributed to ILC2-derived IL-13 acting on HSCs. The increased frequency of ILC2s in fibrotic human liver supports the findings in mice, indicating the possibility of a similar mechanism in humans.
In conclusion, we provide a first detailed characterization of intrahepatic ILCs in nonaffected and fibrotic adult, as well as in fetal liver. Adult intrahepatic ILCs display markers of activation and tissue-residency whereas the exclusive expression of NRP1 and low expression of CD69 on fetal cells indicate LTi functionality and a nontissue-resident phenotype in fetal liver. Furthermore, we show that human intrahepatic ILC2s are increased in fibrotic livers and make up a previously unrecognized source for IL-13, which might act as an important factor in human liver fibrosis. Hence, these findings could have important clinical implications, as targeting ILC2s may present a novel therapeutic strategy when considering treatments options for liver fibrosis.
Material and methods
Collection of patient material
Nonfibrotic liver material was freshly obtained from tumor resection surgeries mostly for colorectal carcinoma metastasis, cholangiocellular carcinoma, or hepatocellular carcinoma. Samples were taken from nontumor affected areas. Severely fibrotic or cirrhotic livers were obtained from liver transplantations mainly due to primary sclerosing cholangitis, but also due to alcoholic cirrhosis, nonalcoholic steatohepatitis, cryptogenic cirrhosis, angiomyolipoma, leiomyosarcoma, Adams Olivier Syndrome, or alpha-1 antitrypsin deficiency. Fibrosis scores were judged according to the Batts/Ludwig classification. Additionally, completely healthy livers of deceased organ donors were obtained. Gut mucosa was obtained from intestinal resection surgeries due to colorectal carcinoma and was taken distally from the tumor. Tonsils were received from adult tonsillectomies due to obstructive sleep disorders. All surgeries were performed at Karolinska University Hospital, Huddinge. Fetal livers from the first trimester (gestational weeks 6-10) were obtained from the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge. In addition, frozen fetal liver cells (gestational week [15] [16] [17] [18] [19] [20] were obtained from the Academic Medical Center, Amsterdam, the Netherlands. Blood from healthy donors was obtained from the Blood Bank at Karolinska University Hospital, Huddinge. For all tissue and blood collection, permission was obtained from the regional ethical board at Karolinska Institutet or from the Medical Ethical Committee of the Academic Medical Center of the University of Amsterdam, the Netherlands. All patients gave their informed consents.
Liver tissue from the deceased organ donors was included in the study according to the regulations for the organ transplantation law of Sweden (1995:831) , that is, the donor's prior written declaration was followed as well as the written and informed consent from next of kin.
Immunohistochemistry (IHC) analysis of IL-33
Five micrometers tissue sections from frozen samples were placed on SuperFrost Ultra Plus slides (Histolab) and stored at -80˚C until staining. Next, sections were air-dried 10 min and fixed in 4% paraformaldehyde (Sigma Aldrich) for 20 min on ice. Sections were incubated with Bloxall (Vector Laboratories) for 10 min and then in Innovex background Buster (Innovex Biosciences) for 20 min at room temperature. Samples were incubated with primary antibody (mouse anti-human IL-33 from Enzo Life Sciences, clone; Nessy-1), at a concentration of 2 μg/mL, overnight in a moisture chamber at 4˚C. Subsequently, sections were incubated with ImmPRESS mouse secondary antibody (Vector Laboratories) for 30 min at room temperature and specific staining was detected by incubation with ImmPACT DAB (Vector Laboratories). Finally, tissue sections were counterstained with Hematoxylin (Histolab) and mounted with Kaisers´s glycerol gelatine (Merck Millipore). Positive staining was visualized by light microscopy (Leica DM 4000B).
IHC-stained specimens were analyzed in a blinded fashion by acquired computerized image analysis (ACIA). Twenty consecutive photomicrographs were taken from each tissue section, which corresponded to the majority of the sample area. The results were analyzed both as ACIA-values, calculated as the percentage of the area that stained positively multiplied by the mean intensity of positive staining, and as frequency of expression, calculated as percentage of positively stained area divided by the total sample area.
Cell isolation
Sections of liver tissue or gut mucosa were cut into small pieces and digested in enzyme buffer (1 mM HEPES in RPMI plus DNase and collagenase II) (both 0.25 mg/mL, Sigma) at 37°C for 30-45 min under magnetic stirring. Digestion was stopped by adding IMDM (Life Technologies) supplemented with 10% fetal calf serum (FCS; Sigma). The cell suspension was filtered through a 100 μm cell strainer and mononuclear cells were enriched using lymphoprep (Axis Shield).
Alternatively, intrahepatic lymphocytes were isolated using a three-step collagenase perfusion protocol on livers obtained after partial or complete hepatectomy. Livers were perfused with warm (37°C) Hank's Buffered Salt Solution (Cambrex invitro) supplemented with Ethylene Glycol Tetraacetic Acid (Sigma); pure Hank's Buffered Salt Solution or Eagle's Minimum Essential Medium with Earle's salts (Cambrex invitro) supplemented with Collagenase XI (Sigma). After digestion, the tissue was transferred into 4°C cold Eagle's Minimum Essential Medium (EMEM), cut in small pieces and filtered through sterile gauze. Collagenases were removed by centrifugation and cell pellets were washed twice in cold EMEM. Hepatocytes were separated by three consecutive centrifugations at 50 g for 5 min at 4°C. The lymphocyte fraction was collected in the supernatant after the first centrifugation step and mononuclear cells were isolated using lymphoprep.
Fetal livers were placed immediately into RPMI medium containing 10% FCS, penicillin, streptomycin, and LZ glutamine (R10 medium) for transport. Subsequently, the tissue was cut into small pieces and incubated in 3-4 mL RPMI containing collagenase II (Sigma; 0.25 mg/mL) and DNAse (Roche; 0.2 mg/mL) under constant magnetic stirring at 37°C for 30-45 min. Cell suspensions were filtered through 5 mL filter top tubes (BD Falcon). Cells were washed twice with 4 mL R10. Alternatively, single cell suspensions were prepared from whole fetal liver tissues as previously described [52] .
Isolated cells were either directly used or frozen in FCS containing 10% DMSO (Sigma), stored in liquid nitrogen for later flow cytometry analysis.
For isolation of lymphocytes from whole tonsils the tissue was minced through a 100 μm cell strainer. The cell suspension was filtered through a 40 μm cell strainer and mononuclear cells were separated using lymphoprep (Axis Shield).
PBMCs were isolated using lymphoprep (Axis Shield).
Flow cytometry analysis of surface and intracellular markers and cell sorting
Cells in single-cell suspensions were analyzed for surface protein expression. In addition, for transcription factor expression by intracellular staining the Foxp3 staining kit (eBioscience) was used. Additionally, the LIVE/DEAD R Fixable Green Dead Cell Stain Kit (Life Technologies) was used. For phenotypical analysis, cells were acquired on a LSR Fortessa (BD Bioscience) using FACS Diva software Version 8 (BD Biosciences). Flow cytometry data were analyzed with FlowJo Software Version 9.6 (TreeStar).
For cell sorting, lymphocytes were predepleted of CD3 + and CD19 + cells using FITC-labeled primary antibodies, anti-FITC microbeads, and MACS depletion columns (Miltenyi Biotech). Cell sorting was performed on an Aria III with the FACS Diva 7 software. For Intracellular cytokine detection, ILC2s were stimulated with PMA (10 ng/mL) (Sigma) and ionomycin (500 nM) (Life Technologies) for 6 h. After 2 h, Golgiplug (BD Biosciences) was added. Intracellular staining of cytokines was performed using Cytofix/Cytoperm (BD Biosciences). All flow cytometry antibodies used are stated in Table 1 .
ILC culture
Sort-purified primary ILC2s from human liver, defined as Lin
Yssel's medium (in-house) containing 1% normal human serum (NHS, Invitrogen) and 500 U/mL IL-2 (Novartis). Irradiated feeder cells consisting of pooled PBMC from three donors (30 Gy) and JY-cells (60 Gy) were added together with 1 μg/mL phytohaemagglutinin (Oxoid, Fisher Scientific) as previously described [13] . Medium was refreshed every three days by replacing half of the volume with 1000 U/mL IL-2 in Yssel's media 1% NHS. After 14 d of culture, ILC2s were rested overnight in 1 U/mL IL-2 in Yssel's media 1% NHS and cultured for 3 d in Yssel's media 1% NHS containing combinations of IL-2 (1 U/mL) (Novartis), IL-33 (50 ng/mL), and TSLP (50 ng/mL) (both from Peprotech).
Culturing and stimulation of Kupffer cells, HSCs, and hepatocytes
Kupffer cells were sorted from liver single-cell suspensions as Lin .000 cells per well were seeded 24-well plates (BD Biosciences) and rested for 36 h in serum-free DMEM before stimulation with poly(I:C). After 6, 12, and 24h, cells were lysed in RLT buffer.
For culturing primary hepatocytes, six-well plates were coated for 30 min with collagen isolated from rat tails (in house). Hepatocytes were plated at 1.5 × 10 6 cells per well in Williams E medium (Sigma), containing 1% Glutamine (Sigma), 1 M HEPES, 10 −8 M insulin, 50 mg/mL gentamycin (Lonza), 250 μg/mL amphotericin B and 5% FCS. After 2 h, medium was changed to WE medium without FCS. Cells were rested overnight, washed two times with 5 mL PBS and stimulated with 50 μg/mL poly(I:C) in 2 mL WE medium. After 3, 6, 12, and 24 h cells were lysed in RLT buffer.
ELISA and multi-plex Immunoassay
For determining cytokine concentrations in supernatants, the PeliKine compact human IL-13 or IFN-γ kit (both from Sanquin) and the human TGF-β1 DuoSet ELISA kit (R&D systems) were used according to the manufacturer's instructions. Plates were read on an iMark Microplate Absorbance Reader (Biorad) and analyzed using Microplate Manager V6.3 software. For measurement of IL-13, IL-5, and IL-4 in supernatants of freshly isolated intrahepatic ILCs a customized 6-plex Human Magnetic Luminex Assay (R&D Systems) was used according to manufacturer instructions and measurements were taken on a MagPix Instrument (BioRad). For display all samples containing nondetectable concentrations were set to half of the lowest detected concentration value.
Quantitative real-time PCR
RNA isolation was performed using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA concentration was measured with a Nanodrop 1000 (Thermo Scientific).
Reverse transcription was performed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. The qPCR reaction was performed in a 7500 Real time PCR system (Applied Biosystems) using the TaqMan universal mastermix II with the TaqMan Gene Expression Assays Hs00263639 m1 for TSLP total and Hs03044841 m1 for IL25 or SYBR R Select Master Mix (all from Applied Biosystems) with primers for IL33, ACTB (Table 2 ). Relative gene expression was analyzed with the Ct method, providing a fold-change of expression normalized to the house-keeping gene ACTB ( Ct) as well as to the nonstimulated control ( Ct). To be able to assess fold-changes also in cases where the gene expression was undetectable in the nonstimulated condition, the nonstimulated condition was set to Ct = 45 that was the maximum number of PCR cycles.
Statistical analysis
For statistical analysis Prism 6 from GraphPad Prism was used. Differences between groups were calculated with Student's t-test or Wilcoxon signed-rank test. Correlation analysis was performed using Pearson's correlation coefficient. D'Agostino and Pearson omnibus normality testing was used for evaluating normality in data distribution. All statistical analysis was confirmed by Statsoft Scandinavia AB (Uppsala, Sweden).
